Article info
PDFClinical and epidemiological research
Extended report
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
- Correspondence to Dr Yusuf Yazici NYU Hospital for Joint Diseases, 246 East 20th Street, NY 10003, USA; yusuf.yazici{at}nyumc.org
Citation
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Publication history
- Accepted August 3, 2011
- First published September 26, 2011.
Online issue publication
September 09, 2020
Article Versions
- Previous version (9 September 2020).
- You are viewing the most recent version of this article.
Web Only Data
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/